But there may be oral GLP-1s for weight loss soon (see: Rybelsus potential Wegovy pill ) and others coming down the research pipeline (see: orforglipron )
Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs
Reputable platforms list active licenses and audit certificates in their footer, complete with verified seals from independent testing labs
Vitamin-C, in its role as an antioxidant, can fight the free radicals that are caused because of prolonged sun exposure, reversing photo-damage effects
Scientists are also now looking into Glutathione as a powerful antioxidant
10.1039/C8MT00142A 67 WangL.HarrisS
